The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Catalytic efficiency determines the in-vivo efficacy of PON1 for detoxifying organophosphorus compounds
Abstract
Human paraoxonase (PON1) is a polymorphic, high-density lipoprotein (HDL)-associated esterase that hydrolyzes the toxic metabolites of several organophosphorus (OP) insecticides and nerve agents. The activity polymorphism is determined by a Gln/Arg (Q/R) substitution at position 192. Injection of purified PON1 protects animals from OP poisoning. In the present study, we investigated the in-vivo function of PON1 for detoxifying organophosphorus insecticides in PON1-knockout mice that were challenged via dermal exposure with diazoxon, diazinon and paraoxon. PON1-knockout mice were extremely sensitive to diazoxon. Doses (2 and 4 mg/kg) that caused no cholinesterase (ChE) inhibition in wild-type mice were lethal to the knockout mice, which also showed slightly increased sensitivity to the parent compound diazinon. Surprisingly, these knockout mice did not show increased sensitivity to paraoxon. In-vitro assays indicated that the PON1R192 isoform hydrolyzed diazoxon less rapidly than did the PON1Q192 isoform. In-vivo analysis, where PON1-knockout mice received the same amount of either PON1(192) isoform via intraperitoneal (i.p.) injection 4 h prior to exposure, showed that both isoforms provided a similar degree of protection against diazoxon, while PON1R192 conferred better protection against chlorpyrifos-oxon than PON1Q192. Injection of purified rabbit PON1 or either human PON1(192) isoform did not protect PONI-knockout mice from paraoxon toxicity, nor did over-expression of the human PON1R192 transgene in wild-type mice. Kinetic analysis of the two human PON1(192) isoforms revealed that the catalytic efficiency (Vmax/Km) determines the in-vivo efficacy of PON1 for organophosphorus detoxication. The results indicate that PON1 plays a major role in the detoxication of diazoxon and chlorpyrifos oxon but not paraoxon.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A new and rapid colorimetric determination of acetylcholinesterase activity
Ellman, G. L., Courtney, K. D., Andres, V., & Featherstone, R. M. (1961) · Biochemical Pharmacology · doi:10.1016/0006-2952(61)90145-9 · Cited by 27,126
Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis
Shih, D. M., Gu, L., Xia, Y.-R., Navab, M., Li, W.-F., Hama, S., Castellani, L. W., Furlong, C. E., Costa, L. G., Fogelman, A. M., et al. (1998) · Nature · doi:10.1038/28406 · Cited by 1,078
Self-citationThe molecular basis of the human serum paraoxonase activity polymorphism
Humbert, R., Adler, D. A., Disteche, C. M., Hassett, C., Omiecinski, C. J., & Furlong, C. E. (1993) · Nature Genetics · doi:10.1038/ng0193-73 · Cited by 841
Self-citationThe effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin
Davies, H. G., Richter, R. J., Keifer, M., Broomfield, C. A., Sowalla, J., & Furlong, C. E. (1996) · Nature Genetics · doi:10.1038/ng1196-334 · Cited by 603
Self-citationAldridge, W. N. (1953) · Biochemical Journal · doi:10.1042/bj0530117 · Cited by 446
BLATTER, M., JAMES, R. W., MESSMER, S., BARJA, F., & POMETTA, D. (1993) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1993.tb17620.x · Cited by 347
Determination of paraoxonase (PON1) status requires more than genotyping
Richter, R. J., & Furlong, C. E. (1999) · Pharmacogenetics · doi:10.1097/00008571-199912000-00009 · Cited by 281
Self-citationFurlong, C. E., Richter, R. J., Seidel, S. L., Costa, L. G., & Motulsky, A. G. (1989) · Analytical Biochemistry · doi:10.1016/0003-2697(89)90424-7 · Cited by 230
Self-citationSerum paraoxonase status: A major factor in determining resistance to organophosphates
Li, W., Costa, L. G., & Furlong, C. E. (1993) · Journal of Toxicology and Environmental Health · doi:10.1080/15287399309531798 · Cited by 167
Self-citationPARAOXON HYDROLYSIS VS. COVALENT BINDING IN THE ELIMINATION OF PARAOXON IN THE RABBIT
Butler, E. G., Eckerson, H. W., & Du, B. N. L. (1985) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)09205-0 · Cited by 19
Cited by
Current issues in organophosphate toxicology
Costa, L. G. (2006) · Clinica Chimica Acta · doi:10.1016/j.cca.2005.10.008 · Cited by 699
Self-citationPope, C., Karanth, S., & Liu, J. (2005) · Environmental Toxicology and Pharmacology · doi:10.1016/j.etap.2004.12.048 · Cited by 320
Eskenazi, B., Huen, K., Marks, A., Harley, K. G., Bradman, A., Barr, D. B., & Holland, N. (2010) · Environmental Health Perspectives · doi:10.1289/ehp.1002234 · Cited by 133
D'Amelio, M., Ricci, I., Sacco, R., Liu, X., D'Agruma, L., Muscarella, L. A., Guarnieri, V, Militerni, R., Bravaccio, C., Elia, M., et al. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001714 · Cited by 125
Decreased serum arylesterase activity in autism spectrum disorders
Gaita, L., Manzi, B., Sacco, R., Lintas, C., Altieri, L., Lombardi, F., Pawlowski, T. L., Redman, M., Craig, D. W., Huentelman, M. J., et al. (2010) · Psychiatry Research · doi:10.1016/j.psychres.2010.04.010 · Cited by 39
Metadata
- Authors
- Li, W.-F., Costa, L. G., Richter, R. J., Hagen, T., Shih, D. M., Tward, A., Lusis, A. J., & Furlong, C. E.
- Venue
- Pharmacogenetics
- Published
- 2000-12
- Volume
- 10
- Issue
- 9
- Pages
- 767-779
- ISSN
- 0960-314X (ISSN-L)
- OpenAlex
- W1995314634
- Cited by
- 276
- References
- 10
- FWCI
- 2.56
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Catalytic efficiency determines the in-vivo efficacy of PON1 for detoxifying organophosphorus compounds. https://app.cochat.ai/papers/10.1097/00008571-200012000-00002
- The paper
- Li, W.-F., Costa, L. G., Richter, R. J., Hagen, T., Shih, D. M., Tward, A., Lusis, A. J., & Furlong, C. E. (2000). Catalytic efficiency determines the in-vivo efficacy of PON1 for detoxifying organophosphorus compounds. Pharmacogenetics. https://doi.org/10.1097/00008571-200012000-00002
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
